Acadia reports Phase 3-enabling Phase 2 topline for remlifanserin in AD psychosis; 60 mg shows nominal CGI-S significance

Acadia announced Phase 3-enabling Phase 2 topline results for remlifanserin in Alzheimer’s disease psychosis, with 60 mg showing nominal significance on CGI-S and favorable safety.Key Highlights:Original SEC Filing: ACADIA PHARMACEUTICALS INC [ ACAD ] - 8-K - Sep. 24, 2026This is an AI-powered summ…